Jump to main content
Jump to site search

Issue 34, 2017
Previous Article Next Article

Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth

Author affiliations

Abstract

Abnormal Wnt activity is a major mechanism responsible for many diseases, including cancer. Previously, we reported that the anthelmintic drug Niclosamide (NIC) inhibits Wnt/β-catenin signaling and suppresses colon cancer cell growth. Although the pharmacokinetic properties of NIC are appropriate for use as an anthelmintic agent, its low solubility, low bioavailability and low systemic exposure limit its usefulness in treating systemic diseases. To overcome these limitations, we conjugated NIC to recombinant chimeric polypeptides (CPs), and the CP-NIC conjugate spontaneously self-assembled into sub-100 nm near-monodisperse nanoparticles. CP-NIC nanoparticles delivered intravenously act as a pro-drug of NIC to dramatically increase exposure of NIC compared to dosing with free NIC. CP-NIC improved anti-tumor activity compared to NIC in a xenograft model of human colon cancer. Because NIC has multiple biological activities, CP-NIC could be used for treatment of multiple diseases, including cancer, bacterial and viral infection, type II diabetes, NASH and NAFLD.

Graphical abstract: Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth

Back to tab navigation

Supplementary files

Publication details

The article was received on 20 Mar 2017, accepted on 31 Jul 2017 and first published on 01 Aug 2017


Article type: Paper
DOI: 10.1039/C7NR01973D
Citation: Nanoscale, 2017,9, 12709-12717
  •   Request permissions

    Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth

    J. Bhattacharyya, X. Ren, R. A. Mook, J. Wang, I. Spasojevic, R. T. Premont, X. Li, A. Chilkoti and W. Chen, Nanoscale, 2017, 9, 12709
    DOI: 10.1039/C7NR01973D

Search articles by author

Spotlight

Advertisements